Reviews Actiq


No reviews yet.

Actiq Drug Description
ACTIQ®
(fentanyl citrate) Oral Transmucosal Lozenge

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR
ABUSE
Reports of serious adverse events, including deaths in patients treated
with ACTIQ® have been reported. Deaths occurred as a result of improper
patient selection (e.g., use in opioid non-tolerant patients) and/or improper
dosing. The substitution of ACTIQ for any other fentanyl product may result
in fatal overdose.
ACTIQ is indicated only for the management of breakthrough cancer pain in
patients with malignancies who are already receiving and who are tolerant to
around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least
8 mg oral hydromorphone daily or an equianalgesic dose of another opioid for
a week or longer.
ACTIQ is not indicated for use in opioid non-tolerant patients including
those with only as needed (PRN) prior exposure.
Life-threatening respiratory depression could occur at any dose in opioid
non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

ACTIQ is contraindicated in the management of acute or postoperative pain
including headache/migraine.
When prescribing, do not convert patients on a mcg per mcg basis to ACTIQ
from other fentanyl products.
When dispensing, do not substitute an ACTIQ prescription for other fentanyl
products. Substantial differences exist in the pharmacokinetic profile of ACTIQ
compared to other fentanyl products that result in clinically important differences
in the extent of absorption of fentanyl. As a result of these differences, the
substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

Special care must be used when dosing ACTIQ. If the breakthrough pain episode
is not relieved 15 minutes after completion of the ACTIQ unit, patients may
take ONLY ONE additional dose using the same strength and then must wait
at least 4 hours before taking another dose [see DOSAGE AND ADMINISTRATION].
ACTIQ contains fentanyl, an opioid agonist and a Schedule II controlled
substance, with an abuse liability similar to other opioid analgesics. ACTIQ
can be abused in a manner similar to other opioid agonists, legal or illicit.
This should be considered when prescribing or dispensing ACTIQ in situations
where the physician or pharmacist is concerned about an increased risk of misuse,
abuse or diversion. Schedule II opioid substances which include morphine, oxycodone,
hydromorphone, oxymorphone, and methadone have the highest potential for abuse
and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that ACTIQ contains a medicine
in an amount which can be fatal to a child. Death has been reported in children
who have accidentally ingested ACTIQ. All units must be kept out of the reach
of children and opened units properly discarded [see WARNINGS AND PRECAUTIONS,
Patient Counseling Information, and HOW
SUPPLIED/Storage And Handling].
ACTIQ is intended to be used only in the care of cancer patients and only by
oncologists and pain specialists who are knowledgeable of and skilled in the
use of Schedule II opioids to treat cancer pain.
The concomitant use of ACTIQ with strong and moderate cytochrome P450 3A4 inhibitors
may result in an increase in fentanyl plasma concentrations, and may cause potentially
fatal respiratory depression [see DRUG INTERACTIONS].

DRUG DESCRIPTION



What are the possible side effects of fentanyl citrate (Actiq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl citrate and call your doctor at once if you have any of these serious side effects:

shallow breathing, slow heart rate;
extreme sleepiness; or
feeling light-headed, fainting.

Less serious side effects may include:

dry mouth;
headache, dizziness,...
Read All Potential Side Effects for Actiq »




ACTIQ (oral transmucosal fentanyl citrate) is a solid formulation of fentanyl
citrate, a potent opioid analgesic, intended for oral transmucosal administration.
ACTIQ is formulated as a white to off-white solid drug matrix on a handle that
is fracture resistant (ABS plastic) under normal conditions when used as directed.
ACTIQ is designed to be dissolved slowly in the mouth to facilitate transmucosal
absorption. The handle allows the ACTIQ unit to be removed from the mouth if
signs of excessive opioid effects appear during administration.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








Inactive Ingredients: Hydrated dextrates, citric acid, dibasic sodium phosphate, artificial berry flavor, magnesium stearate, and edible glue (modified
food starch and confectioner's sugar).
Last reviewed on RxList: 12/1/2009




Actiq Drug Description
ACTIQ®
(fentanyl citrate) Oral Transmucosal Lozenge

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR
ABUSE
Reports of serious adverse events, including deaths in patients treated
with ACTIQ® have been reported. Deaths occurred as a result of improper
patient selection (e.g., use in opioid non-tolerant patients) and/or improper
dosing. The substitution of ACTIQ for any other fentanyl product may result
in fatal overdose.
ACTIQ is indicated only for the management of breakthrough cancer pain in
patients with malignancies who are already receiving and who are tolerant to
around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least
8 mg oral hydromorphone daily or an equianalgesic dose of another opioid for
a week or longer.
ACTIQ is not indicated for use in opioid non-tolerant patients including
those with only as needed (PRN) prior exposure.
Life-threatening respiratory depression could occur at any dose in opioid
non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

ACTIQ is contraindicated in the management of acute or postoperative pain
including headache/migraine.
When prescribing, do not convert patients on a mcg per mcg basis to ACTIQ
from other fentanyl products.
When dispensing, do not substitute an ACTIQ prescription for other fentanyl
products. Substantial differences exist in the pharmacokinetic profile of ACTIQ
compared to other fentanyl products that result in clinically important differences
in the extent of absorption of fentanyl. As a result of these differences, the
substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

Special care must be used when dosing ACTIQ. If the breakthrough pain episode
is not relieved 15 minutes after completion of the ACTIQ unit, patients may
take ONLY ONE additional dose using the same strength and then must wait
at least 4 hours before taking another dose [see DOSAGE AND ADMINISTRATION].
ACTIQ contains fentanyl, an opioid agonist and a Schedule II controlled
substance, with an abuse liability similar to other opioid analgesics. ACTIQ
can be abused in a manner similar to other opioid agonists, legal or illicit.
This should be considered when prescribing or dispensing ACTIQ in situations
where the physician or pharmacist is concerned about an increased risk of misuse,
abuse or diversion. Schedule II opioid substances which include morphine, oxycodone,
hydromorphone, oxymorphone, and methadone have the highest potential for abuse
and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that ACTIQ contains a medicine
in an amount which can be fatal to a child. Death has been reported in children
who have accidentally ingested ACTIQ. All units must be kept out of the reach
of children and opened units properly discarded [see WARNINGS AND PRECAUTIONS,
Patient Counseling Information, and HOW
SUPPLIED/Storage And Handling].
ACTIQ is intended to be used only in the care of cancer patients and only by
oncologists and pain specialists who are knowledgeable of and skilled in the
use of Schedule II opioids to treat cancer pain.
The concomitant use of ACTIQ with strong and moderate cytochrome P450 3A4 inhibitors
may result in an increase in fentanyl plasma concentrations, and may cause potentially
fatal respiratory depression [see DRUG INTERACTIONS].

DRUG DESCRIPTION



What are the possible side effects of fentanyl citrate (Actiq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl citrate and call your doctor at once if you have any of these serious side effects:

shallow breathing, slow heart rate;
extreme sleepiness; or
feeling light-headed, fainting.

Less serious side effects may include:

dry mouth;
headache, dizziness,...
Read All Potential Side Effects for Actiq »




ACTIQ (oral transmucosal fentanyl citrate) is a solid formulation of fentanyl
citrate, a potent opioid analgesic, intended for oral transmucosal administration.
ACTIQ is formulated as a white to off-white solid drug matrix on a handle that
is fracture resistant (ABS plastic) under normal conditions when used as directed.
ACTIQ is designed to be dissolved slowly in the mouth to facilitate transmucosal
absorption. The handle allows the ACTIQ unit to be removed from the mouth if
signs of excessive opioid effects appear during administration.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








Inactive Ingredients: Hydrated dextrates, citric acid, dibasic sodium phosphate, artificial berry flavor, magnesium stearate, and edible glue (modified
food starch and confectioner's sugar).
Last reviewed on RxList: 12/1/2009




Actiq Drug Description
ACTIQ®
(fentanyl citrate) Oral Transmucosal Lozenge

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR
ABUSE
Reports of serious adverse events, including deaths in patients treated
with ACTIQ® have been reported. Deaths occurred as a result of improper
patient selection (e.g., use in opioid non-tolerant patients) and/or improper
dosing. The substitution of ACTIQ for any other fentanyl product may result
in fatal overdose.
ACTIQ is indicated only for the management of breakthrough cancer pain in
patients with malignancies who are already receiving and who are tolerant to
around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least
8 mg oral hydromorphone daily or an equianalgesic dose of another opioid for
a week or longer.
ACTIQ is not indicated for use in opioid non-tolerant patients including
those with only as needed (PRN) prior exposure.
Life-threatening respiratory depression could occur at any dose in opioid
non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

ACTIQ is contraindicated in the management of acute or postoperative pain
including headache/migraine.
When prescribing, do not convert patients on a mcg per mcg basis to ACTIQ
from other fentanyl products.
When dispensing, do not substitute an ACTIQ prescription for other fentanyl
products. Substantial differences exist in the pharmacokinetic profile of ACTIQ
compared to other fentanyl products that result in clinically important differences
in the extent of absorption of fentanyl. As a result of these differences, the
substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

Special care must be used when dosing ACTIQ. If the breakthrough pain episode
is not relieved 15 minutes after completion of the ACTIQ unit, patients may
take ONLY ONE additional dose using the same strength and then must wait
at least 4 hours before taking another dose [see DOSAGE AND ADMINISTRATION].
ACTIQ contains fentanyl, an opioid agonist and a Schedule II controlled
substance, with an abuse liability similar to other opioid analgesics. ACTIQ
can be abused in a manner similar to other opioid agonists, legal or illicit.
This should be considered when prescribing or dispensing ACTIQ in situations
where the physician or pharmacist is concerned about an increased risk of misuse,
abuse or diversion. Schedule II opioid substances which include morphine, oxycodone,
hydromorphone, oxymorphone, and methadone have the highest potential for abuse
and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that ACTIQ contains a medicine
in an amount which can be fatal to a child. Death has been reported in children
who have accidentally ingested ACTIQ. All units must be kept out of the reach
of children and opened units properly discarded [see WARNINGS AND PRECAUTIONS,
Patient Counseling Information, and HOW
SUPPLIED/Storage And Handling].
ACTIQ is intended to be used only in the care of cancer patients and only by
oncologists and pain specialists who are knowledgeable of and skilled in the
use of Schedule II opioids to treat cancer pain.
The concomitant use of ACTIQ with strong and moderate cytochrome P450 3A4 inhibitors
may result in an increase in fentanyl plasma concentrations, and may cause potentially
fatal respiratory depression [see DRUG INTERACTIONS].

DRUG DESCRIPTION



What are the possible side effects of fentanyl citrate (Actiq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl citrate and call your doctor at once if you have any of these serious side effects:

shallow breathing, slow heart rate;
extreme sleepiness; or
feeling light-headed, fainting.

Less serious side effects may include:

dry mouth;
headache, dizziness,...
Read All Potential Side Effects for Actiq »




ACTIQ (oral transmucosal fentanyl citrate) is a solid formulation of fentanyl
citrate, a potent opioid analgesic, intended for oral transmucosal administration.
ACTIQ is formulated as a white to off-white solid drug matrix on a handle that
is fracture resistant (ABS plastic) under normal conditions when used as directed.
ACTIQ is designed to be dissolved slowly in the mouth to facilitate transmucosal
absorption. The handle allows the ACTIQ unit to be removed from the mouth if
signs of excessive opioid effects appear during administration.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








Inactive Ingredients: Hydrated dextrates, citric acid, dibasic sodium phosphate, artificial berry flavor, magnesium stearate, and edible glue (modified
food starch and confectioner's sugar).
Last reviewed on RxList: 12/1/2009




Actiq Drug Description
ACTIQ®
(fentanyl citrate) Oral Transmucosal Lozenge

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR
ABUSE
Reports of serious adverse events, including deaths in patients treated
with ACTIQ® have been reported. Deaths occurred as a result of improper
patient selection (e.g., use in opioid non-tolerant patients) and/or improper
dosing. The substitution of ACTIQ for any other fentanyl product may result
in fatal overdose.
ACTIQ is indicated only for the management of breakthrough cancer pain in
patients with malignancies who are already receiving and who are tolerant to
around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least
8 mg oral hydromorphone daily or an equianalgesic dose of another opioid for
a week or longer.
ACTIQ is not indicated for use in opioid non-tolerant patients including
those with only as needed (PRN) prior exposure.
Life-threatening respiratory depression could occur at any dose in opioid
non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

ACTIQ is contraindicated in the management of acute or postoperative pain
including headache/migraine.
When prescribing, do not convert patients on a mcg per mcg basis to ACTIQ
from other fentanyl products.
When dispensing, do not substitute an ACTIQ prescription for other fentanyl
products. Substantial differences exist in the pharmacokinetic profile of ACTIQ
compared to other fentanyl products that result in clinically important differences
in the extent of absorption of fentanyl. As a result of these differences, the
substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

Special care must be used when dosing ACTIQ. If the breakthrough pain episode
is not relieved 15 minutes after completion of the ACTIQ unit, patients may
take ONLY ONE additional dose using the same strength and then must wait
at least 4 hours before taking another dose [see DOSAGE AND ADMINISTRATION].
ACTIQ contains fentanyl, an opioid agonist and a Schedule II controlled
substance, with an abuse liability similar to other opioid analgesics. ACTIQ
can be abused in a manner similar to other opioid agonists, legal or illicit.
This should be considered when prescribing or dispensing ACTIQ in situations
where the physician or pharmacist is concerned about an increased risk of misuse,
abuse or diversion. Schedule II opioid substances which include morphine, oxycodone,
hydromorphone, oxymorphone, and methadone have the highest potential for abuse
and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that ACTIQ contains a medicine
in an amount which can be fatal to a child. Death has been reported in children
who have accidentally ingested ACTIQ. All units must be kept out of the reach
of children and opened units properly discarded [see WARNINGS AND PRECAUTIONS,
Patient Counseling Information, and HOW
SUPPLIED/Storage And Handling].
ACTIQ is intended to be used only in the care of cancer patients and only by
oncologists and pain specialists who are knowledgeable of and skilled in the
use of Schedule II opioids to treat cancer pain.
The concomitant use of ACTIQ with strong and moderate cytochrome P450 3A4 inhibitors
may result in an increase in fentanyl plasma concentrations, and may cause potentially
fatal respiratory depression [see DRUG INTERACTIONS].

DRUG DESCRIPTION



What are the possible side effects of fentanyl citrate (Actiq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl citrate and call your doctor at once if you have any of these serious side effects:

shallow breathing, slow heart rate;
extreme sleepiness; or
feeling light-headed, fainting.

Less serious side effects may include:

dry mouth;
headache, dizziness,...
Read All Potential Side Effects for Actiq »




ACTIQ (oral transmucosal fentanyl citrate) is a solid formulation of fentanyl
citrate, a potent opioid analgesic, intended for oral transmucosal administration.
ACTIQ is formulated as a white to off-white solid drug matrix on a handle that
is fracture resistant (ABS plastic) under normal conditions when used as directed.
ACTIQ is designed to be dissolved slowly in the mouth to facilitate transmucosal
absorption. The handle allows the ACTIQ unit to be removed from the mouth if
signs of excessive opioid effects appear during administration.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








Inactive Ingredients: Hydrated dextrates, citric acid, dibasic sodium phosphate, artificial berry flavor, magnesium stearate, and edible glue (modified
food starch and confectioner's sugar).
Last reviewed on RxList: 12/1/2009




Actiq Drug Description
ACTIQ®
(fentanyl citrate) Oral Transmucosal Lozenge

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR
ABUSE
Reports of serious adverse events, including deaths in patients treated
with ACTIQ® have been reported. Deaths occurred as a result of improper
patient selection (e.g., use in opioid non-tolerant patients) and/or improper
dosing. The substitution of ACTIQ for any other fentanyl product may result
in fatal overdose.
ACTIQ is indicated only for the management of breakthrough cancer pain in
patients with malignancies who are already receiving and who are tolerant to
around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least
8 mg oral hydromorphone daily or an equianalgesic dose of another opioid for
a week or longer.
ACTIQ is not indicated for use in opioid non-tolerant patients including
those with only as needed (PRN) prior exposure.
Life-threatening respiratory depression could occur at any dose in opioid
non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

ACTIQ is contraindicated in the management of acute or postoperative pain
including headache/migraine.
When prescribing, do not convert patients on a mcg per mcg basis to ACTIQ
from other fentanyl products.
When dispensing, do not substitute an ACTIQ prescription for other fentanyl
products. Substantial differences exist in the pharmacokinetic profile of ACTIQ
compared to other fentanyl products that result in clinically important differences
in the extent of absorption of fentanyl. As a result of these differences, the
substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

Special care must be used when dosing ACTIQ. If the breakthrough pain episode
is not relieved 15 minutes after completion of the ACTIQ unit, patients may
take ONLY ONE additional dose using the same strength and then must wait
at least 4 hours before taking another dose [see DOSAGE AND ADMINISTRATION].
ACTIQ contains fentanyl, an opioid agonist and a Schedule II controlled
substance, with an abuse liability similar to other opioid analgesics. ACTIQ
can be abused in a manner similar to other opioid agonists, legal or illicit.
This should be considered when prescribing or dispensing ACTIQ in situations
where the physician or pharmacist is concerned about an increased risk of misuse,
abuse or diversion. Schedule II opioid substances which include morphine, oxycodone,
hydromorphone, oxymorphone, and methadone have the highest potential for abuse
and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that ACTIQ contains a medicine
in an amount which can be fatal to a child. Death has been reported in children
who have accidentally ingested ACTIQ. All units must be kept out of the reach
of children and opened units properly discarded [see WARNINGS AND PRECAUTIONS,
Patient Counseling Information, and HOW
SUPPLIED/Storage And Handling].
ACTIQ is intended to be used only in the care of cancer patients and only by
oncologists and pain specialists who are knowledgeable of and skilled in the
use of Schedule II opioids to treat cancer pain.
The concomitant use of ACTIQ with strong and moderate cytochrome P450 3A4 inhibitors
may result in an increase in fentanyl plasma concentrations, and may cause potentially
fatal respiratory depression [see DRUG INTERACTIONS].

DRUG DESCRIPTION



What are the possible side effects of fentanyl citrate (Actiq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl citrate and call your doctor at once if you have any of these serious side effects:

shallow breathing, slow heart rate;
extreme sleepiness; or
feeling light-headed, fainting.

Less serious side effects may include:

dry mouth;
headache, dizziness,...
Read All Potential Side Effects for Actiq »




ACTIQ (oral transmucosal fentanyl citrate) is a solid formulation of fentanyl
citrate, a potent opioid analgesic, intended for oral transmucosal administration.
ACTIQ is formulated as a white to off-white solid drug matrix on a handle that
is fracture resistant (ABS plastic) under normal conditions when used as directed.
ACTIQ is designed to be dissolved slowly in the mouth to facilitate transmucosal
absorption. The handle allows the ACTIQ unit to be removed from the mouth if
signs of excessive opioid effects appear during administration.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








Inactive Ingredients: Hydrated dextrates, citric acid, dibasic sodium phosphate, artificial berry flavor, magnesium stearate, and edible glue (modified
food starch and confectioner's sugar).
Last reviewed on RxList: 12/1/2009





Other reviews about Actiq on wordpress

Buy Actiq Online Order Cheap Actiq Generic Purchase Discount Without Prescription
  by worlddnews
FOLLOW THIS LINK FOR ENTER TO TRUSTED & REPUTABLE ONLINE DRUGSTORE WHERE YOU CAN GET ALL QUALIFIED INFORMATION ABOUT Actiq ONLINE     Your chest also contains and allergen in home […]


March of the Clones
  by Law Offices of Sadaka Associates
For those of you who don't know, when a drug is approved by the Federal Food and Drug Administration (FDA) it receives an indication which specifies its use. […]


Cephalon's FDA Warning More of a Formality (CEPH)
  by 247wallst
Cephalon Inc. (NASDAQ:CEPH) is a biotech that has been under a bit of a low ceiling after its recent blunder regarding FENTORA.  As a reminder FENTORA is that […]


THE ACTIQ® AND FENTORA® ACCESS PROBLEM
  by painresearchadvocates
The Problem ACTIQ® and Fentora® are commercially formulated fentanyl products that dissolve under the tongue or in the inner side of the jaw ("buccal administration"). These products are simply […]


Fired over a Lollipop
  by sobercollege
David Brennan, a former quality-assurance auditor for the pharmaceutical company Cephalon Inc., claims he was fired in February for reporting concerns about Actiq, a narcotic painkiller that looks […]


Cephalon Announces Exercise of $65 Million Over-allotment Option ... - PR Newswire (press release)
  by waismannmethod
Cephalon Announces Exercise of $65 Million Over-allotment Option ...PR Newswire (press release), NY... TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(R) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl […]


The Rise of Short- and Rapid-Acting Opioids - Genetic Engineering News (press release)
  by waismannmethod
The Rise of Short- and Rapid-Acting OpioidsGenetic Engineering News (press release)Cephalon launched a follow-on product to Actiq in 2006 in the US Fentora (buccal fentanyl) is an effervescent […]


FENTANYL SAFETY LABEL CHANGE
  by KIRBY JOHNSON, PC
New boxed warning for users of Actiq's fentanyl.  The following sentences were added to the boxed warning: The substitution of Actiq for any other fentanyl product may result in […]


Breakthrough Pain
  by -
Breakthrough Pain is defined as;  pain (The International Association for the Study of Pain defines pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue […]


Actiq® and Fentora® are two drugs used a
  by ltpepperlaw
Actiq® and Fentora® are two drugs used as painkillers. The active ingredient is fentanyl. Generally these drugs are prescribed to people who are considered opiod tolerant (those on […]



Other reviews about Actiq on web:

WARNING: IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR ABUSE. Reports of serious adverse events, including deaths in patients treated with ACTIQ® have been ... ACTIQ


Actiq by Cephalon, is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa. Actiq - Wikipedia, the free encyclopedia


Actiq (fentanyl citrate) treats breakthrough cancer pain that is not controlled by other medicines. Includes Actiq side effects, interactions and indications. Actiq Information from Drugs.com


Learn about the prescription medication Actiq (Fentanyl Citrate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Actiq (Fentanyl Citrate) Drug Information: Uses, Side Effects ...


Accurate, FDA approved Actiq information for healthcare professionals and patients - brought to you by Drugs.com. Actiq Official FDA information, side effects and uses.


Key Information regarding the safe use of ACTIQ: ACTIQ is used to treat breakthrough pain in adult patients with cancer (16 years and older) who are already taking other opioid pain ... Key Information regarding the safe use of ACTIQ:


Actiq, complete drug information. Including Actiq common uses, side effects and warnings. Actiq


LifeSciencesWorld is your online resource for biotechnology, pharmaceutical, medical devices and life sciences industries. Barr Launches Generic ACTIQ(R) Cancer Pain Management Product ...


Drug information and side-effects for Actiq ... Useful Websites. Medical Tourism Compare and save on surgery Global Translations Actiq - Drug information from MediLexicon


Actiq is a treatment for breakthrough cancer pain in cancer patients 16 years of age and older. The medication is only prescribed to patients who are already taking opioid pain ... Actiq Side Effects, Uses, & Interactions





Featured Reviews

Reviews Somatropin

Nutropin AQ Drug Description Nutropin AQ® [somatropin (rDNA origin)] Injection DRUG DESCRIPTION What are the possible side effects of somatropin? If you have Prader-Willi syndrome, call your doctor promptly if you develop signs...
Read More  |  Review This
Reviews Lybrel

Lybrel Drug Description LYBREL® (90 mcg levonorgestrel and 20 mcg ethinyl estradiol) Tablets Patients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases...
Read More  |  Review This
Reviews Methoxsalen Capsules

Oxsoralen-Ultra Drug Description Oxoralen-Ultra® (methoxsalen) Capsules, USP, 10 mg CAUTION: METHOXSALEN IS A POTENT DRUG. READ ENTIRE BROCHURE PRIOR TO PRESCRIBING OR DISPENSING THIS MEDICATION. Methoxsalen with UV radiation...
Read More  |  Review This
Reviews Vaccinia Immune Globulin Intravenous

VIGIV Drug Description VIGIV Vaccinia Immune Globulin Intravenous (Human) DRUG DESCRIPTION CNJ-016, Vaccinia Immune Globulin Intravenous (Human) (VIGIV), is a solvent/detergent-treated sterile solution of purified gamma globulin (IgG)...
Read More  |  Review This
Reviews Bupropion Hydrobromide Tablet

Aplenzin Drug Description Aplenzin (bupropion hydrobromide) Tablet, Film Coated, Extended Release for Oral use SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicida...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....